Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Keith Alan Johnson, M.D.

Co-Author

This page shows the publications co-authored by Keith Johnson and Reisa Sperling.
Connection Strength

21.298
  1. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019 02; 85(2):181-193.
    View in: PubMed
    Score: 0.821
  2. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016 Jan; 79(1):110-9.
    View in: PubMed
    Score: 0.662
  3. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron. 2014 Nov 05; 84(3):608-22.
    View in: PubMed
    Score: 0.613
  4. Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria. Continuum (Minneap Minn). 2013 Apr; 19(2 Dementia):325-38.
    View in: PubMed
    Score: 0.549
  5. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol. 2013 01; 9(1):54-8.
    View in: PubMed
    Score: 0.536
  6. Dementia: new criteria but no new treatments. Lancet Neurol. 2012 Jan; 11(1):4-5.
    View in: PubMed
    Score: 0.503
  7. To sleep, perchance to delay dementia. Arch Neurol. 2012 Jan; 69(1):118-20.
    View in: PubMed
    Score: 0.503
  8. Pro: Can biomarkers be gold standards in Alzheimer's disease? Alzheimers Res Ther. 2010 Jun 25; 2(3):17.
    View in: PubMed
    Score: 0.453
  9. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 2010 Mar; 12(1):27-43.
    View in: PubMed
    Score: 0.443
  10. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009 Jul 30; 63(2):178-88.
    View in: PubMed
    Score: 0.426
  11. In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline. Sci Transl Med. 2021 09 22; 13(612):eabj2511.
    View in: PubMed
    Score: 0.247
  12. Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. Neurology. 2021 04 06; 96(14):e1844-e1854.
    View in: PubMed
    Score: 0.237
  13. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography. Sci Transl Med. 2021 01 20; 13(577).
    View in: PubMed
    Score: 0.236
  14. Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. Ann Neurol. 2020 11; 88(5):921-932.
    View in: PubMed
    Score: 0.229
  15. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurol. 2020 06 01; 77(6):735-745.
    View in: PubMed
    Score: 0.226
  16. The presubiculum links incipient amyloid and tau pathology to memory function in older persons. Neurology. 2020 05 05; 94(18):e1916-e1928.
    View in: PubMed
    Score: 0.223
  17. Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. J Alzheimers Dis. 2020; 75(4):1437-1446.
    View in: PubMed
    Score: 0.219
  18. Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. Neuroimage Clin. 2019; 24:102097.
    View in: PubMed
    Score: 0.217
  19. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019 Aug 01; 76(8):915-924.
    View in: PubMed
    Score: 0.213
  20. Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture. Cereb Cortex. 2019 07 22; 29(8):3445-3456.
    View in: PubMed
    Score: 0.212
  21. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol. 2019 05 01; 76(5):542-551.
    View in: PubMed
    Score: 0.209
  22. An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. J Alzheimers Dis. 2019; 68(3):1161-1170.
    View in: PubMed
    Score: 0.204
  23. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. J Alzheimers Dis. 2019; 67(2):757-768.
    View in: PubMed
    Score: 0.204
  24. Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity. J Neurosci. 2019 01 16; 39(3):548-556.
    View in: PubMed
    Score: 0.203
  25. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat Med. 2018 12; 24(12):1910-1918.
    View in: PubMed
    Score: 0.202
  26. Amyloid-associated increases in longitudinal report of subjective cognitive complaints. Alzheimers Dement (N Y). 2018; 4:444-449.
    View in: PubMed
    Score: 0.200
  27. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurol. 2018 05 01; 75(5):548-556.
    View in: PubMed
    Score: 0.195
  28. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci. 2018 03; 21(3):424-431.
    View in: PubMed
    Score: 0.192
  29. 18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. J Alzheimers Dis. 2018; 62(4):1691-1702.
    View in: PubMed
    Score: 0.191
  30. Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. JAMA Neurol. 2017 07 01; 74(7):813-820.
    View in: PubMed
    Score: 0.184
  31. Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. Neuroimage Clin. 2017; 15:408-414.
    View in: PubMed
    Score: 0.183
  32. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017 Apr; 81(4):583-596.
    View in: PubMed
    Score: 0.181
  33. Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. Neurology. 2017 May 02; 88(18):1759-1767.
    View in: PubMed
    Score: 0.181
  34. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease. Neuropsychologia. 2017 05; 99:343-349.
    View in: PubMed
    Score: 0.181
  35. Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging Behav. 2017 04; 11(2):383-390.
    View in: PubMed
    Score: 0.181
  36. Tau and amyloid ß proteins distinctively associate to functional network changes in the aging brain. Alzheimers Dement. 2017 Nov; 13(11):1261-1269.
    View in: PubMed
    Score: 0.181
  37. Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. J Neurosci. 2017 04 19; 37(16):4323-4331.
    View in: PubMed
    Score: 0.181
  38. Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology. 2017 Apr 11; 88(15):1431-1438.
    View in: PubMed
    Score: 0.180
  39. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß. Alzheimers Dement. 2017 Sep; 13(9):1004-1012.
    View in: PubMed
    Score: 0.180
  40. Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry. 2016 Dec 01; 73(12):1230-1237.
    View in: PubMed
    Score: 0.177
  41. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA Neurol. 2016 Nov 01; 73(11):1334-1341.
    View in: PubMed
    Score: 0.176
  42. Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurol. 2016 Oct 01; 73(10):1185-1191.
    View in: PubMed
    Score: 0.175
  43. Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology. 2016 Aug 30; 87(9):920-6.
    View in: PubMed
    Score: 0.173
  44. In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. J Neurosci. 2016 07 13; 36(28):7364-74.
    View in: PubMed
    Score: 0.172
  45. Decreased hippocampal metabolism in high-amyloid mild cognitive impairment. Alzheimers Dement. 2016 12; 12(12):1288-1296.
    View in: PubMed
    Score: 0.172
  46. Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging. Neuroimage. 2016 05 15; 132:334-343.
    View in: PubMed
    Score: 0.168
  47. Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. Neurobiol Aging. 2016 Apr; 40:61-67.
    View in: PubMed
    Score: 0.166
  48. Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology. 2015 Jul 07; 85(1):48-55.
    View in: PubMed
    Score: 0.160
  49. Amyloid-ß deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain. 2015 Apr; 138(Pt 4):1023-35.
    View in: PubMed
    Score: 0.156
  50. Synergistic effect of ß-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014 Nov; 71(11):1379-85.
    View in: PubMed
    Score: 0.153
  51. Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults. J Neurosci. 2014 Apr 09; 34(15):5200-10.
    View in: PubMed
    Score: 0.147
  52. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13.
    View in: PubMed
    Score: 0.147
  53. Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum. J Alzheimers Dis. 2014; 41(3):719-28.
    View in: PubMed
    Score: 0.145
  54. Functional connectivity in Alzheimer's disease: measurement and meaning. Biol Psychiatry. 2013 Sep 01; 74(5):318-9.
    View in: PubMed
    Score: 0.141
  55. Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology. 2013 Aug 20; 81(8):736-44.
    View in: PubMed
    Score: 0.140
  56. In vivo characterization of the early states of the amyloid-beta network. Brain. 2013 Jul; 136(Pt 7):2239-52.
    View in: PubMed
    Score: 0.140
  57. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013 Oct; 9(5 Suppl):S72-83.
    View in: PubMed
    Score: 0.136
  58. Apathy is associated with increased amyloid burden in mild cognitive impairment. J Neuropsychiatry Clin Neurosci. 2013; 25(4):302-7.
    View in: PubMed
    Score: 0.135
  59. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging. 2013 Mar; 34(3):822-31.
    View in: PubMed
    Score: 0.131
  60. The ups and downs of the posteromedial cortex: age- and amyloid-related functional alterations of the encoding/retrieval flip in cognitively normal older adults. Cereb Cortex. 2013 Jun; 23(6):1317-28.
    View in: PubMed
    Score: 0.129
  61. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Apr; 2(4):a006213.
    View in: PubMed
    Score: 0.128
  62. Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord. 2011; 31(6):443-50.
    View in: PubMed
    Score: 0.122
  63. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011 Jul; 49(9):2776-83.
    View in: PubMed
    Score: 0.121
  64. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011 Jun; 134(Pt 6):1635-46.
    View in: PubMed
    Score: 0.120
  65. Amyloid-ß associated cortical thinning in clinically normal elderly. Ann Neurol. 2011 Jun; 69(6):1032-42.
    View in: PubMed
    Score: 0.119
  66. Age and amyloid-related alterations in default network habituation to stimulus repetition. Neurobiol Aging. 2012 Jul; 33(7):1237-52.
    View in: PubMed
    Score: 0.119
  67. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A. 2010 Jun 01; 107(22):10256-61.
    View in: PubMed
    Score: 0.112
  68. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010 Mar; 67(3):353-64.
    View in: PubMed
    Score: 0.111
  69. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009 Feb 11; 29(6):1860-73.
    View in: PubMed
    Score: 0.103
  70. 18F-florbetapir Positron Emission Tomography-determined Cerebral ß-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery. Anesthesiology. 2018 04; 128(4):728-744.
    View in: PubMed
    Score: 0.097
  71. Intelligence quotient-adjusted memory impairment is associated with abnormal single photon emission computed tomography perfusion. J Int Neuropsychol Soc. 2007 Sep; 13(5):821-31.
    View in: PubMed
    Score: 0.093
  72. Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2021; 13(1):e12243.
    View in: PubMed
    Score: 0.062
  73. Association of cortical microstructure with amyloid-ß and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. Mol Psychiatry. 2021 Sep 29.
    View in: PubMed
    Score: 0.062
  74. Cortical thickness across the lifespan in a Colombian cohort with autosomal-dominant Alzheimer's disease: A cross-sectional study. Alzheimers Dement (Amst). 2021; 13(1):e12233.
    View in: PubMed
    Score: 0.062
  75. Plasma IL-12/IFN-? axis predicts cognitive trajectories in cognitively unimpaired older adults. Alzheimers Dement. 2021 Jun 23.
    View in: PubMed
    Score: 0.061
  76. Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology. 2021 May 05.
    View in: PubMed
    Score: 0.060
  77. Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease. Alzheimers Dement. 2021 05; 17(5):813-821.
    View in: PubMed
    Score: 0.059
  78. Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimers Res Ther. 2021 01 15; 13(1):27.
    View in: PubMed
    Score: 0.059
  79. Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2020; 12(1):e12132.
    View in: PubMed
    Score: 0.059
  80. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. JAMA Neurol. 2020 12 01; 77(12):1504-1513.
    View in: PubMed
    Score: 0.058
  81. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nat Commun. 2020 11 27; 11(1):6024.
    View in: PubMed
    Score: 0.058
  82. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. Neurology. 2021 01 26; 96(4):e619-e631.
    View in: PubMed
    Score: 0.058
  83. Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimers Dement (Amst). 2020; 12(1):e12118.
    View in: PubMed
    Score: 0.058
  84. Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimers Res Ther. 2020 10 29; 12(1):138.
    View in: PubMed
    Score: 0.058
  85. Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. J Int Neuropsychol Soc. 2021 05; 27(5):426-438.
    View in: PubMed
    Score: 0.058
  86. Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. JAMA Neurol. 2020 10 01; 77(10):1288-1298.
    View in: PubMed
    Score: 0.058
  87. Correction: Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry. 2020 Oct; 25(10):2644.
    View in: PubMed
    Score: 0.058
  88. The neurophysiology and seizure outcomes of late onset unexplained epilepsy. Clin Neurophysiol. 2020 11; 131(11):2667-2672.
    View in: PubMed
    Score: 0.058
  89. The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 09 10; 12(1):104.
    View in: PubMed
    Score: 0.057
  90. Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimer's disease. Neuroimage Clin. 2020; 28:102407.
    View in: PubMed
    Score: 0.057
  91. Multiple markers contribute to risk of progression from normal to mild cognitive impairment. Neuroimage Clin. 2020; 28:102400.
    View in: PubMed
    Score: 0.057
  92. Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 08 21; 12(1):99.
    View in: PubMed
    Score: 0.057
  93. Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology. 2020 09 08; 95(10):e1312-e1321.
    View in: PubMed
    Score: 0.057
  94. Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiol Dis. 2020 08; 142:104960.
    View in: PubMed
    Score: 0.056
  95. Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. Neuroimage. 2020 10 15; 220:116991.
    View in: PubMed
    Score: 0.056
  96. Functional and Pathological Correlates of Judgments of Learning in Cognitively Unimpaired Older Adults. Cereb Cortex. 2020 03 14; 30(3):1974-1983.
    View in: PubMed
    Score: 0.056
  97. Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. Neurobiol Aging. 2020 09; 93:124-130.
    View in: PubMed
    Score: 0.055
  98. Word retrieval across the biomarker-confirmed Alzheimer's disease syndromic spectrum. Neuropsychologia. 2020 03 16; 140:107391.
    View in: PubMed
    Score: 0.055
  99. Associations of Widowhood and ß-Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. JAMA Netw Open. 2020 02 05; 3(2):e200121.
    View in: PubMed
    Score: 0.055
  100. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimers Dement. 2020 03; 16(3):552-560.
    View in: PubMed
    Score: 0.055
  101. Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2020 03; 91(3):330-332.
    View in: PubMed
    Score: 0.055
  102. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019 11; 25(11):1680-1683.
    View in: PubMed
    Score: 0.054
  103. Longitudinal degradation of the default/salience network axis in symptomatic individuals with elevated amyloid burden. Neuroimage Clin. 2020; 26:102052.
    View in: PubMed
    Score: 0.054
  104. Associations of Physical Activity and ß-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurol. 2019 Oct 01; 76(10):1203-1210.
    View in: PubMed
    Score: 0.054
  105. Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. Alzheimers Dement (Amst). 2019 Dec; 11:670-678.
    View in: PubMed
    Score: 0.054
  106. Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. Ann Neurol. 2019 10; 86(4):616-625.
    View in: PubMed
    Score: 0.053
  107. Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Netw Open. 2019 08 02; 2(8):e198964.
    View in: PubMed
    Score: 0.053
  108. Synergism between fornix microstructure and beta amyloid accelerates memory decline in clinically normal older adults. Neurobiol Aging. 2019 09; 81:38-46.
    View in: PubMed
    Score: 0.052
  109. Social Engagement and Amyloid-ß-Related Cognitive Decline in Cognitively Normal Older Adults. Am J Geriatr Psychiatry. 2019 11; 27(11):1247-1256.
    View in: PubMed
    Score: 0.052
  110. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiol Aging. 2019 06; 78:178-185.
    View in: PubMed
    Score: 0.052
  111. Global White Matter Diffusion Characteristics Predict Longitudinal Cognitive Change Independently of Amyloid Status in Clinically Normal Older Adults. Cereb Cortex. 2019 03 01; 29(3):1251-1262.
    View in: PubMed
    Score: 0.052
  112. Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer's disease. Alzheimers Res Ther. 2019 02 04; 11(1):17.
    View in: PubMed
    Score: 0.051
  113. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. Alzheimers Res Ther. 2019 01 31; 11(1):14.
    View in: PubMed
    Score: 0.051
  114. Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. Alzheimers Res Ther. 2019 01 10; 11(1):4.
    View in: PubMed
    Score: 0.051
  115. Vascular Risk and ß-Amyloid Are Synergistically Associated with Cortical Tau. Ann Neurol. 2019 02; 85(2):272-279.
    View in: PubMed
    Score: 0.051
  116. Regional tau pathology and loneliness in cognitively normal older adults. Transl Psychiatry. 2018 12 18; 8(1):282.
    View in: PubMed
    Score: 0.051
  117. Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. Neuroimage. 2019 02 01; 186:446-454.
    View in: PubMed
    Score: 0.051
  118. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Alzheimers Dement. 2019 03; 15(3):487-496.
    View in: PubMed
    Score: 0.051
  119. Dedifferentiation of caudate functional connectivity and striatal dopamine transporter density predict memory change in normal aging. Proc Natl Acad Sci U S A. 2018 10 02; 115(40):10160-10165.
    View in: PubMed
    Score: 0.050
  120. Interactive Associations of Vascular Risk and ß-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study. JAMA Neurol. 2018 09 01; 75(9):1124-1131.
    View in: PubMed
    Score: 0.050
  121. Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry. 2020 10; 25(10):2599-2607.
    View in: PubMed
    Score: 0.050
  122. Sex, amyloid, and APOE e4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement. 2018 09; 14(9):1193-1203.
    View in: PubMed
    Score: 0.049
  123. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018 10; 14(10):1281-1292.
    View in: PubMed
    Score: 0.049
  124. White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. PLoS One. 2018; 13(5):e0195838.
    View in: PubMed
    Score: 0.049
  125. Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. Brain. 2018 05 01; 141(5):1486-1500.
    View in: PubMed
    Score: 0.049
  126. Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. Am J Psychiatry. 2018 06 01; 175(6):530-537.
    View in: PubMed
    Score: 0.048
  127. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global ß-Amyloid Burden. JAMA Neurol. 2017 12 01; 74(12):1455-1463.
    View in: PubMed
    Score: 0.047
  128. The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. Alzheimers Dement (Amst). 2018; 10:121-129.
    View in: PubMed
    Score: 0.047
  129. Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals. Neuroimage Clin. 2018; 17:388-396.
    View in: PubMed
    Score: 0.047
  130. Functional network integrity presages cognitive decline in preclinical Alzheimer disease. Neurology. 2017 Jul 04; 89(1):29-37.
    View in: PubMed
    Score: 0.046
  131. The association between tau PET and retrospective cortical thinning in clinically normal elderly. Neuroimage. 2017 08 15; 157:612-622.
    View in: PubMed
    Score: 0.046
  132. Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia. 2017 06; 100:164-170.
    View in: PubMed
    Score: 0.046
  133. Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. Am J Geriatr Psychiatry. 2017 Jul; 25(7):683-693.
    View in: PubMed
    Score: 0.045
  134. Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. J Alzheimers Dis. 2017; 59(3):975-985.
    View in: PubMed
    Score: 0.045
  135. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. J Alzheimers Dis. 2017; 60(4):1451-1459.
    View in: PubMed
    Score: 0.045
  136. Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. J Prev Alzheimers Dis. 2017; 4(2):81-86.
    View in: PubMed
    Score: 0.045
  137. Epicenters of dynamic connectivity in the adaptation of the ventral visual system. Hum Brain Mapp. 2017 04; 38(4):1965-1976.
    View in: PubMed
    Score: 0.044
  138. Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. Ann Neurol. 2016 12; 80(6):846-857.
    View in: PubMed
    Score: 0.044
  139. The influence of demographic factors on subjective cognitive concerns and beta-amyloid. Int Psychogeriatr. 2017 04; 29(4):645-652.
    View in: PubMed
    Score: 0.044
  140. Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One. 2016; 11(9):e0163669.
    View in: PubMed
    Score: 0.044
  141. A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. J Mol Neurosci. 2016 Nov; 60(3):354-361.
    View in: PubMed
    Score: 0.043
  142. Trans-pQTL study identifies immune crosstalk between Parkinson and Alzheimer loci. Neurol Genet. 2016 Aug; 2(4):e90.
    View in: PubMed
    Score: 0.043
  143. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016 Aug 02; 87(5):539-47.
    View in: PubMed
    Score: 0.043
  144. Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. J Alzheimers Dis. 2016 06 18; 53(3):1097-105.
    View in: PubMed
    Score: 0.043
  145. Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. Lancet Neurol. 2016 07; 15(8):811-819.
    View in: PubMed
    Score: 0.043
  146. Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One. 2016; 11(3):e0152082.
    View in: PubMed
    Score: 0.042
  147. Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. Neurobiol Aging. 2016 06; 42:177-88.
    View in: PubMed
    Score: 0.042
  148. The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease. J Prev Alzheimers Dis. 2015 Dec; 2(4):242-253.
    View in: PubMed
    Score: 0.041
  149. Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. Neuropsychology. 2016 07; 30(5):624-30.
    View in: PubMed
    Score: 0.041
  150. Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity. Hum Brain Mapp. 2016 Feb; 37(2):621-31.
    View in: PubMed
    Score: 0.041
  151. CD33 modulates TREM2: convergence of Alzheimer loci. Nat Neurosci. 2015 Nov; 18(11):1556-8.
    View in: PubMed
    Score: 0.041
  152. Massachusetts Alzheimer's Disease Research Center: progress and challenges. Alzheimers Dement. 2015 Oct; 11(10):1241-5.
    View in: PubMed
    Score: 0.040
  153. Estimating Total Cerebral Microinfarct Burden From Diffusion-Weighted Imaging. Stroke. 2015 Aug; 46(8):2129-35.
    View in: PubMed
    Score: 0.040
  154. Subjective cognitive concerns, amyloid-ß, and neurodegeneration in clinically normal elderly. Neurology. 2015 Jul 07; 85(1):56-62.
    View in: PubMed
    Score: 0.040
  155. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia. 2015 Jul; 73:169-75.
    View in: PubMed
    Score: 0.040
  156. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015; 7(1):26.
    View in: PubMed
    Score: 0.040
  157. Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology. 2015 May 26; 84(21):2153-60.
    View in: PubMed
    Score: 0.040
  158. Harvard Aging Brain Study: Dataset and accessibility. Neuroimage. 2017 01; 144(Pt B):255-258.
    View in: PubMed
    Score: 0.039
  159. Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. J Alzheimers Dis. 2015; 46(3):727-35.
    View in: PubMed
    Score: 0.039
  160. Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. J Alzheimers Dis. 2015; 46(1):63-73.
    View in: PubMed
    Score: 0.039
  161. Functional Activities Questionnaire Items that Best Discriminate and Predict Progression from Clinically Normal to Mild Cognitive Impairment. Curr Alzheimer Res. 2015; 12(5):493-502.
    View in: PubMed
    Score: 0.039
  162. The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. J Alzheimers Dis. 2015; 47(2):421-32.
    View in: PubMed
    Score: 0.039
  163. Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum. Alzheimer Dis Assoc Disord. 2015 Jan-Mar; 29(1):18-25.
    View in: PubMed
    Score: 0.039
  164. Partial volume correction in quantitative amyloid imaging. Neuroimage. 2015 Feb 15; 107:55-64.
    View in: PubMed
    Score: 0.039
  165. Apathy is associated with lower inferior temporal cortical thickness in mild cognitive impairment and normal elderly individuals. J Neuropsychiatry Clin Neurosci. 2015; 27(1):e22-7.
    View in: PubMed
    Score: 0.038
  166. Multiple Brain Markers are Linked to Age-Related Variation in Cognition. Cereb Cortex. 2016 Apr; 26(4):1388-400.
    View in: PubMed
    Score: 0.038
  167. Amyloid and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014 May 20; 82(20):1760-7.
    View in: PubMed
    Score: 0.037
  168. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol. 2014 Apr; 75(4):597-601.
    View in: PubMed
    Score: 0.037
  169. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry. 2014 Dec; 22(12):1642-51.
    View in: PubMed
    Score: 0.037
  170. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum. J Alzheimers Dis. 2014; 42(1):291-300.
    View in: PubMed
    Score: 0.036
  171. SIST-M-IR activities of daily living items that best discriminate clinically normal elderly from those with mild cognitive impairment. Curr Alzheimer Res. 2014; 11(8):785-91.
    View in: PubMed
    Score: 0.036
  172. Everyday cognition scale items that best discriminate between and predict progression from clinically normal to mild cognitive impairment. Curr Alzheimer Res. 2014; 11(9):853-61.
    View in: PubMed
    Score: 0.036
  173. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):E4502-9.
    View in: PubMed
    Score: 0.036
  174. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013 Jul 30; 81(5):487-500.
    View in: PubMed
    Score: 0.035
  175. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry. 2014 Nov; 22(11):1168-79.
    View in: PubMed
    Score: 0.035
  176. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013 Jul; 16(7):848-50.
    View in: PubMed
    Score: 0.035
  177. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci. 2012 Nov 14; 32(46):16233-42.
    View in: PubMed
    Score: 0.033
  178. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum. Dement Geriatr Cogn Disord. 2012; 34(2):96-111.
    View in: PubMed
    Score: 0.033
  179. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012 Oct; 50(12):2880-2886.
    View in: PubMed
    Score: 0.033
  180. Amyloid-ß assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012 Oct 16; 79(16):1636-44.
    View in: PubMed
    Score: 0.033
  181. Apolipoprotein E e4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013 Jan; 34(1):1-12.
    View in: PubMed
    Score: 0.032
  182. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90.
    View in: PubMed
    Score: 0.032
  183. Aß Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012 Feb; 39(2):209-19.
    View in: PubMed
    Score: 0.032
  184. Failure to modulate attentional control in advanced aging linked to white matter pathology. Cereb Cortex. 2012 May; 22(5):1038-51.
    View in: PubMed
    Score: 0.030
  185. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement. 2011 Jul; 7(4):474-485.e4.
    View in: PubMed
    Score: 0.030
  186. Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2011 May; 7(3):300-8.
    View in: PubMed
    Score: 0.030
  187. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009 Oct 07; 29(40):12686-94.
    View in: PubMed
    Score: 0.027
  188. The role of neuroimaging in elucidating delirium pathophysiology. J Gerontol A Biol Sci Med Sci. 2006 Dec; 61(12):1287-93.
    View in: PubMed
    Score: 0.022
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.